Rockville, Md. (April 28, 2025) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic, platelet-derived, cellular therapeutics, today announced the appointment of Randall Stanicky to our Board of Directors.
Mr. Stanicky brings over two decades of capital markets experience and deep industry relationships, having previously held senior roles at Goldman Sachs and the RBC Capital Markets. Since 2021, he has served as Chief Financial Officer of Click Therapeutics, where he successfully led both Series B and Series C fundraising rounds to support the company’s growth and strategic objectives.
“We’re thrilled to welcome Randall to our Board of Directors,” said Mike Gaffney, Chief Executive Officer of Cellphire Therapeutics. “His deep expertise in finance and proven ability to raise capital in complex environments will be instrumental as we continue to advance our pipeline and prepare for future stages of growth.” “His experience aligns perfectly with our long-term vision, and I look forward to working with him as we guide Cellphire through its next chapter of development.”
“Randall brings a unique combination of financial expertise, strategic insight, and a strong track record of execution,” said Tom Dubin, Chairman of the Board of Cellphire Therapeutics. “We’re excited to welcome him to the Board and look forward to the contributions he’ll make as we seek to deliver on our mission to transform patient care with innovative platelet-based therapeutics.”
About Cellphire Therapeutics
Cellphire Therapeutics, Inc.’s vision: No one should die from controllable hemorrhage. A private, clinical stage biotechnology company developing next-generation platelet-derived therapies, Cellphire has a portfolio of platelet-derived biologics including two assets in clinical development: its late-stage biologic CLPH-511, a cryopreserved platelet (CPP) therapy with extended shelf life, and CLPH-211, part of the FPH® family of freeze-dried, platelet-derived hemostatic agents. Once approved, Cellphire’s differentiated technologies will address significant unmet health system and medical unmet needs across various clinical settings including acute bleeding associated with cardiac surgery, trauma and traumatic brain injury. For more information, visit www.Cellphire.com.
Robert Woods
VP, Business Operations
RWoods@Cellphire.com